{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T17:00:19Z","timestamp":1785344419669,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,29]]},"DOI":"10.7759\/cureus.113605","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T16:15:16Z","timestamp":1785341716000},"source":"Crossref","is-referenced-by-count":0,"title":["Metastatic Uterine Sarcomas: A Retrospective Analysis on Clinical Outcomes and Biology"],"prefix":"10.7759","author":[{"given":"Neha","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita Rungta","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roma","family":"Jethani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachariah","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhil","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal Krishna","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ipsita","family":"Dhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal Ranjan","family":"Vinayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipinesh","family":"Sansar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish Group for Research on Sarcomas (GEIS)","volume":"15","author":"P\u00e9rez-Fidalgo JA","year":"2023","unstructured":"P\u00e9rez-Fidalgo JA, Ortega E, Ponce J, et al.. Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish Group for Research on Sarcomas (GEIS). Ther Adv Med Oncol. 2023, 15:17588359231157645.","journal-title":"Ther Adv Med Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2023.06.016","article-title":"Uterine sarcomas: a critical review of the literature","volume":"287","author":"Giannini A","year":"2023","unstructured":"Giannini A, Golia D'Aug\u00e8 T, Bogani G, et al.. Uterine sarcomas: a critical review of the literature. Eur J Obstet Gynecol Reprod Biol. 2023, 287:166-70. 10.1016\/j.ejogrb.2023.06.016","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2024-005823","article-title":"ESGO\/EURACAN\/GCIG guidelines for the management of patients with uterine sarcomas","volume":"34","author":"Ray-Coquard I","year":"2024","unstructured":"Ray-Coquard I, Casali PG, Croce S, et al.. ESGO\/EURACAN\/GCIG guidelines for the management of patients with uterine sarcomas. Int J Gynecol Cancer. 2024, 34:1499-521. 10.1136\/ijgc-2024-005823","journal-title":"Int J Gynecol Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_350955","article-title":"Uterine sarcomas: how to navigate an ever-growing list of subtypes","volume":"42","author":"Roy M","year":"2022","unstructured":"Roy M, Musa F, Taylor SE, Huang M. Uterine sarcomas: how to navigate an ever-growing list of subtypes. Am Soc Clin Oncol Educ Book. 2022, 42:1-10. 10.1200\/EDBK_350955","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.07.031","article-title":"Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group","volume":"167","author":"Croce S","year":"2022","unstructured":"Croce S, Devouassoux-Shisheboran M, Pautier P, et al.. Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group. Gynecol Oncol. 2022, 167:373-89. 10.1016\/j.ygyno.2022.07.031","journal-title":"Gynecol Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.65819","article-title":"Prognostic factors in uterine sarcoma based on the tumor size stratification: a retrospective study","volume":"16","author":"Asano F","year":"2024","unstructured":"Asano F, Morisada T, Momomura M, Shibuya H, Matsumoto H, Kobayashi Y. Prognostic factors in uterine sarcoma based on the tumor size stratification: a retrospective study. Cureus. 2024, 16:e65819. 10.7759\/cureus.65819","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2022-004204","article-title":"Prognostic factors in patients with uterine sarcoma: the SARCUT study","volume":"33","author":"Zapardiel I","year":"2023","unstructured":"Zapardiel I, Gracia Segovia M, Macuks R, et al.. Prognostic factors in patients with uterine sarcoma: the SARCUT study. Int J Gynecol Cancer. 2023, 33:897-904. 10.1136\/ijgc-2022-004204","journal-title":"Int J Gynecol Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10129-x","article-title":"Clinical characteristics and prognosis analysis of uterine sarcoma: a single-institution retrospective study","volume":"22","author":"Wang F","year":"2022","unstructured":"Wang F, Dai X, Chen H, Hu X, Wang Y. Clinical characteristics and prognosis analysis of uterine sarcoma: a single-institution retrospective study. BMC Cancer. 2022, 22:1050. 10.1186\/s12885-022-10129-x","journal-title":"BMC Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer EA","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al.. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009, 45:228-47. 10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.211658","article-title":"MRI evaluation of uterine masses for risk of leiomyosarcoma: a consensus statement","volume":"306","author":"Hindman N","year":"2023","unstructured":"Hindman N, Kang S, Fournier L, et al.. MRI evaluation of uterine masses for risk of leiomyosarcoma: a consensus statement. Radiology. 2023, 306:e211658. 10.1148\/radiol.211658","journal-title":"Radiology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2015.139","article-title":"Practical issues in uterine pathology from banal to bewildering: the remarkable spectrum of smooth muscle neoplasia","volume":"29","author":"Oliva E","year":"2016","unstructured":"Oliva E. Practical issues in uterine pathology from banal to bewildering: the remarkable spectrum of smooth muscle neoplasia. Mod Pathol. 2016, 29:S104-20. 10.1038\/modpathol.2015.139","journal-title":"Mod Pathol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2022.03.007","article-title":"Discrepancies in pathological diagnosis of endometrial stromal sarcoma: a multi-institutional retrospective study from the Japanese clinical oncology group","volume":"124","author":"Yoshida H","year":"2022","unstructured":"Yoshida H, Kikuchi A, Tsuda H, et al.. Discrepancies in pathological diagnosis of endometrial stromal sarcoma: a multi-institutional retrospective study from the Japanese clinical oncology group. Hum Pathol. 2022, 124:24-35. 10.1016\/j.humpath.2022.03.007","journal-title":"Hum Pathol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-021-00928-y","article-title":"What clinical trials are needed for treatment of leiomyosarcoma?","volume":"23","author":"Kasper B","year":"2022","unstructured":"Kasper B, D'Ambrosio L, Davis EJ, et al.. What clinical trials are needed for treatment of leiomyosarcoma?. Curr Treat Options Oncol. 2022, 23:439-49. 10.1007\/s11864-021-00928-y","journal-title":"Curr Treat Options Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00380-1","article-title":"Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial","volume":"23","author":"Pautier P","year":"2022","unstructured":"Pautier P, Italiano A, Piperno-Neumann S, et al.. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2022, 23:1044-54. 10.1016\/S1470-2045(22)00380-1","journal-title":"Lancet Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3781","article-title":"Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology\/Gynecologic Oncology Group study","volume":"33","author":"Hensley ML","year":"2015","unstructured":"Hensley ML, Miller A, O'Malley DM, Mannel RS, Behbakht K, Bakkum-Gamez JN, Michael H. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology\/Gynecologic Oncology Group study. J Clin Oncol. 2015, 33:1180-5. 10.1200\/JCO.2014.58.3781","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17111893","article-title":"Endometrial stromal sarcoma: an update","volume":"17","author":"Ricotta G","year":"2025","unstructured":"Ricotta G, Russo SA, Fagotti A, et al.. Endometrial stromal sarcoma: an update. Cancers (Basel). 2025, 17:1893. 10.3390\/cancers17111893","journal-title":"Cancers (Basel)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30622-8","article-title":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial","volume":"18","author":"Seddon B","year":"2017","unstructured":"Seddon B, Strauss SJ, Whelan J, et al.. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017, 18:1397-410. 10.1016\/S1470-2045(17)30622-8","journal-title":"Lancet Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.03.010","article-title":"Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial","volume":"109","author":"Hensley ML","year":"2008","unstructured":"Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008, 109:329-34. 10.1016\/j.ygyno.2008.03.010","journal-title":"Gynecol Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16010192","article-title":"A ten-year real-life experience with pazopanib in uterine leyomiosarcoma in two high-specialized centers in Italy: effectiveness and safety","volume":"16","author":"Mantiero M","year":"2023","unstructured":"Mantiero M, Bini M, Polignano M, et al.. A ten-year real-life experience with pazopanib in uterine leyomiosarcoma in two high-specialized centers in Italy: effectiveness and safety. Cancers (Basel). 2023, 16:192. 10.3390\/cancers16010192","journal-title":"Cancers (Basel)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2018.29.e3","article-title":"Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study","volume":"29","author":"Kim HJ","year":"2018","unstructured":"Kim HJ, Kim Y, Lee SJ, Lee J, Park SH. Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study. J Gynecol Oncol. 2018, 29:e3. 10.3802\/jgo.2018.29.e3","journal-title":"J Gynecol Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.02.024","article-title":"Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study","volume":"109","author":"Hensley ML","year":"2008","unstructured":"Hensley ML, Blessing JA, Degeest K, Abulafia O, Rose PG, Homesley HD. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol. 2008, 109:323-8. 10.1016\/j.ygyno.2008.02.024","journal-title":"Gynecol Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2044","article-title":"Hormonal therapy in uterine sarcomas","volume":"8","author":"Zang Y","year":"2019","unstructured":"Zang Y, Dong M, Zhang K, Gao C, Guo F, Wang Y, Xue F. Hormonal therapy in uterine sarcomas. Cancer Med. 2019, 8:1339-49. 10.1002\/cam4.2044","journal-title":"Cancer Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14040921","article-title":"New insights into hormonal therapies in uterine sarcomas","volume":"14","author":"Maccaroni E","year":"2022","unstructured":"Maccaroni E, Lunerti V, Agostinelli V, Giampieri R, Zepponi L, Pagliacci A, Berardi R. New insights into hormonal therapies in uterine sarcomas. Cancers (Basel). 2022, 14:921. 10.3390\/cancers14040921","journal-title":"Cancers (Basel)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2022.101044","article-title":"Clinical use of PARP inhibitor in recurrent uterine leiomyosarcoma with presence of a somatic BRCA2 mutation","volume":"42","author":"Shammas N","year":"2022","unstructured":"Shammas N, Yang T, Abidi A, Amneus M, Hodeib M. Clinical use of PARP inhibitor in recurrent uterine leiomyosarcoma with presence of a somatic BRCA2 mutation. Gynecol Oncol Rep. 2022, 42:101044. 10.1016\/j.gore.2022.101044","journal-title":"Gynecol Oncol Rep"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00765","article-title":"Retrospective analysis of BRCA-altered uterine sarcoma treated with poly(ADP-ribose) polymerase inhibitors","volume":"9","author":"Rao M","year":"2025","unstructured":"Rao M, Merrill M, Troxel M, Chiang S, Momeni-Boroujeni A, Hensley ML, Schram AM. Retrospective analysis of BRCA-altered uterine sarcoma treated with poly(ADP-ribose) polymerase inhibitors. JCO Precis Oncol. 2025, 9:e2400765. 10.1200\/PO-24-00765","journal-title":"JCO Precis Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/517807-metastatic-uterine-sarcomas-a-retrospective-analysis-on-clinical-outcomes-and-biology","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T16:15:17Z","timestamp":1785341717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/517807-metastatic-uterine-sarcomas-a-retrospective-analysis-on-clinical-outcomes-and-biology"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.113605","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,29]]}}}